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Abstract
Purpose The objective of this study was to evaluate the
value of 18F-FDG PET/CT and S-100B tumour marker for
the detection of liver metastases from uveal melanoma in
comparison to liver metastases from cutaneous melanoma.
Methods A retrospective evaluation was conducted of 27
liver metastases in 13 patients with uveal melanoma (UM)
(mean age: 56.8, range: 30–77) and 43 liver metastases in 14
patients (mean age: 57.9, range: 40–82) with cutaneous
melanoma (CM) regarding size and FDG uptake by measur-
ing the maximum standardized uptake value (SUVmax).
S-100B serum tumour markers were available in 20 patients.
Cytology, histology, additional morphological imaging and
follow-up served as reference standard. In nine patients liver
metastases were further evaluated histologically regarding
GLUT-1 and S-100 receptor expression and regarding
epithelial or spindle cell growth pattern.
Results Of 27 liver metastases in 6 of 13 patients (46%)
with UM, 16 (59%) were FDG negative, whereas all
liver metastases from CM were positive. Liver metasta-
ses from UM showed significantly (p<0.001) lower
SUVmax (mean: 3.5, range: 1.5–13.4) compared with liver
metastases from CM (mean: 6.6, range: 2.3–15.3). In
four of six (66.7%) patients with UM and liver
metastases S-100B was normal and in two (33.3%)
increased. All PET-negative liver metastases were detect-
able by morphological imaging (CT or MRI). S-100B
was abnormal in 13 of 14 patients with liver metastases
from CM. S-100B values were significantly higher (p=
0.007) in the CM patient group (mean S-100B: 10.9 μg/l,
range: 0.1–115 μg/l) compared with the UM patients
(mean: 0.2 μg/l, range: 0.0–0.5 μg/l). Histological work-
up of the liver metastases showed no obvious difference in
GLUT-1 or S-100 expression between UM and CM liver
metastases. The minority (36%) of patients with UM had
extrahepatic metastases and the majority (86%) of patients
with CM had extrahepatic metastases, respectively. There
was a close to significant trend to better survival of UM
patients compared with CM patients (p=0.06).
Conclusion FDG PET/CT and serum S-100B are not
sensitive enough for the detection of liver metastases
from UM, whereas liver metastases from cutaneous
melanoma are reliably FDG positive and lead regularly
to increased S-100B tumour markers. The reason for the
lower FDG uptake in UM liver metastases remains
unclear. We recommend to perform combined contrast-
enhanced PET/CT in order to detect FDG-negative liver
metastases from UM.
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Introduction
FDG PET/CT is increasingly used for initial staging and
restaging of patients with cutaneous melanoma (CM). PET/
CT has the highest impact in patients with high-risk
melanoma. We define patients with CM as “high-risk” if
one of the following criteria is fulfilled: Breslow tumour
thickness > 4 mm, Clark level III or IV or known resected
metastases in the prior history. FDG PET/CT showed a high
accuracy for the detection of metastases from CM, helps to
select patients for surgery and has impact on patient
survival [1–4].
Uveal melanoma (UM) is a rare type of melanoma but
the most common primary intraocular malignancy in adults.
Over the last decades a stable incidence of UM in the USA
and Europe with four to seven cases per million has been
observed [5, 6]. The pattern of metastatic spread differs
from CM. Because of the absence of lymphatic drainage of
the eye UM metastasizes haematogeneously predominantly
into the liver [7]. Despite the common origin of both
melanoma types deriving from melanocytes, both melano-
mas show marked differences in their metastatic potential,
clinical response to treatments, immune response and
genetic alterations. The genetic alterations in cutaneous
melanomas are well described but not much is known about
the genetic alterations associated with the development of
UM because of the small number of biopsy samples [8]. It
has been demonstrated that abnormalities related to chro-
mosomes 3, 6 and 8 are strongly related to this tumor and
are associated with a reduction of survival from 95 to less
than 50% [9].
The reason for the high affinity of UM metastases to the
liver is not known. Factors such as tumour size, ciliary
body involvement, cell type, extravascular matrix patterns
and cytogenetics seem to be related to the presence of
distant metastases [10]. Detection of liver metastases is
crucial because they are the life-limiting component of the
disease in the majority the patients and treatment improves
survival in selected patients. Prognosis of metastatic UM is
very poor with a median survival of 19 months without
liver metastases and only 7 months with liver metastases.
Patients with resectable liver metastases may profit from
surgical resection [11]. Systemic therapies have poor
response rates (1%) in unresectable cases. Chemoemboliza-
tion seems to be effective, inducing responses in about 36%
of the patients [12–15]. New treatment options like
treatment with 90Y-microspheres are promising [16].
In patients with CM serum S-100B is a useful tumour
marker, indicating the presence of distant metastases and
reflecting the tumour burden. In addition, S-100B has
prognostic implications [17–22]. The literature on the
prognostic and diagnostic value of S-100B in patients with
UM is controversial [23–25].
The aim of this study was to evaluate the value of 18F-FDG
PET/CT and the tumour marker S-100B regarding the
detection of liver metastases from uveal melanoma in
comparison to liver metastases from cutaneous melanoma.
Materials and methods
Patients
This retrospective study contains 27 melanoma patients (12
women, 15 men); 13 patients (mean age: 56.8 years, range:
30–77 years) had a history of UM and 14 patients (mean
age: 57.9 years, range: 40–82 years) had a history of CM.
All patients had proven liver metastases of UM or CM. A
FDG PET/CT scan was performed in all patients for staging
or restaging between November 2002 and March 2008. No
systemic treatment was performed before the PET/CT
investigations. Patient characteristics are summarized in
Table 1.
We received approval from our Institutional Review
Board to undertake this retrospective study.
Tumour marker S-100B measurement
The determination of serum S-100B was performed with
a commercially available enzyme-linked immunosorbent
assay (ELISA) kit (Sangtec 100 ELISA, Diasorin Inc.,
Stillwater, MN, USA) according to the instructions of the
manufacturer. A normal cut-upper limit was defined as
0.2 μg/l (the 95th percentile of blood donor samples).
Values ≥0.3 μg/l were taken to be an indication for
melanoma metastases. The detection limit is 0.03 μl/
l (BO+3 SD). Intra-assay and inter-assay precision was
estimated by analysis of variance (ANOVA). The “within
run” and “total run” reproducibility was within 10%.
In all patients S-100B levels were determined before
therapy at the time point of the PET/CT investigation (less
than 7 days interval between S-100B measurement and
PET/CT.
Reference standard
In eleven patients the presence of liver metastases was
proven by cytology (n=1) or histology (n=10). In the
remaining 17 patients a combined reference was used: all
patients additionally had morphological imaging (contrast-
enhanced CT and/or MRI of the liver). In 19 patients
follow-up imaging with PET/CT was available. Altogeth-
er, 71 follow-up PET/CT examinations were performed
(mean: 3.7, range: 0–13). In the surviving patients we had
a mean clinical follow-up time of 18 months (range:
3–37 months).
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PET/CT imaging protocol
All data were acquired on a combined PET/CT in-line
system (Discovery LS, Discovery RX, Discovery STE, GE
Health Systems, Milwaukee, WI, USA).
Patients fasted for at least 4 h prior to the scanning,
which started approximately 60 min after the injection of
350–400 MBq of 18F-FDG. In patients with primary CM
distally to the groin a whole-body PET/CT was performed;
in the remaining patients a partial body PET/CT was
performed with exclusion of the legs. All patients were
tested for a normal glucose level before scanning. Patients
with elevated glucose levels were rescheduled and scanned
with normal glucose levels. PET/CT imaging was per-
formed as described previously [26].
Overall, 96 PET/CT scans were performed in these 27
patients. For the evaluation only the PET/CT images were
used, which were performed at the time point of the
diagnosis of liver metastases.
PET/CT interpretation and measurement of SUVmax
The PET/CT images were reviewed and analysed by an
experienced nuclear radiology physician without knowl-
edge of the results of other imaging studies. The PET
images and the corresponding CT images of the PET/CT
study were analysed for the presence and nature of focal
lesions with an increased 18F-FDG uptake in the liver or
outside the liver. For all patients, the attenuation-corrected
PET images were analysed. Lesions were interpreted as
metastases if the uptake was higher than the uptake of the
surrounding background tissue and thus a focal lesion was
clearly depictable. FDG uptake in physiological or benign
variants such as uptake into muscles or pulmonary
infiltration were excluded from the analysis.
Semiquantitative analysis of FDG uptake in all suspi-
cious lesions was performed by measuring the maximum
standardized uptake value (SUVmax). SUVmax measure-
ments were performed as previously described [27].
Histological evaluation of liver metastases
The tumour samples were retrieved from the archive of the
Institute of Surgical Pathology of our institution. All tumour
tissues were fixed in buffered 4% formalin, embedded in
paraffin and 2 thick slides were cut for standard haematoxylin
and eosin (H&E) staining (Figs. 1, 2, 3 and 4).
Immunohistochemistry
Immunohistochemistry was performed on 2-μm thick
paraffin sections using the Ventana Benchmark automated
staining system (Ventana Medical Systems, Tucson, AZ,
USA) with Ventana reagents for the entire procedure.
Primary antibodies against protein S-100 (DAKO Cytoma-
tion, Glostrup, Denmark; dilution 1:1000) and GLUT-1
(Chemicon Intl. Inc; dilution 1:1000) were detected using
the iVIEW DAB or Ventana AP PAR detection kit (yielding
a brown or red reaction product, respectively). Slides were
counterstained with haematoxylin. The quality of the
reactions was controlled on tissue slides with known
reaction patterns stained in parallel with the probes
examined. Expression of GLUT-1 and S-100 was graded
visually with a 4-point scale (0=negative, 1= discretely
positive, 2= moderately positive, 3= markedly positive).
Statistical analysis
Data were analysed on a patient basis using SPSS 15 for
Windows (SPSS Inc.). Statistical significance was assessed
with the sign test. A pvalue<0.05 was considered to
indicate a significant difference. The log-rank test was
calculated for the overall survival.
Results
FDG uptake in liver metastases
Of 27 liver metastases in 6 out of 13 patients (46%) with UM,
16 (59%) were FDG negative (Figs. 1 and 2), whereas all liver
metastases (100%) from CM were positive in all patients
(100%) (Figs. 3). Liver metastases from UM showed
significantly (p=0.008) lower SUVmax (mean: 3.5, range:
1.5–13.4) compared with liver metastases from CM (mean:
6.6, range: 2.3–15.3, p<0.001). All PET-negative liver
metastases were detectable by morphological imaging. Table 1
shows results and Table 2 box plots of SUVmax values.
S-100B values
S-100B serum measurements were available in six patients
with UM metastases. S-100B was normal in four of six
patients with UM and liver metastases and increased in two.
S-100B was abnormal in 13 of 14 patients with liver
metastases from CM. S-100B values were significantly
higher in the CM patient group (mean S-100B: 10.9 μg/l,
range :0.1–115 μg/l) compared with the UM patients
(mean: 0.2 μg/l, range: 0.0–0.5 μg/l, p=0.007).
Histological evaluation of liver metastases
The two FDG-negative liver metastases from UM showed a
spindle cell-like growth pattern. The two FDG-active liver
metastases from UM showed epithelial growth patterns like
all the histological findings from CM. All histological
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findings from UM and CM showed positivity for S-100.
One liver metastasis from UM and two liver metastases
from CM showed no GLUT-1 expression despite FDG
uptake on the PET/CT images.
Extrahepatic metastases
Of 13 patients with UM, 9 (69%) had no extrahepatic
metastases. Of 13 patients with UM, 4 (31%) had
Fig. 2 a Liver metastasis
(patient 4) of a predominantly
spindle cell, partially pigmented
malignant melanoma of the
uvea. Residual liver tissue at
lower left. H&E staining,
original magnification ×100. b
Strong immunohistochemical
positivity (red reaction product)
for the melanocytic marker
S-100, original magnification
×200. c Immunohistochemical
negativity of the melanoma cells
for GLUT-1. Internal positive
control of erythrocytes (red).
Original magnification ×200
Fig. 1 A 30-year-old female patient (patient 4) 4 years after therapy
for an uveal melanoma. FDG PET/CT (a, b, d, e) images without
pathological uptake in the liver. Serum S-100B was normal. Contrast-
enhanced CT (c, f) showing two hypodense lesions in the liver. The
liver lesions were resected and metastases from the UM were
confirmed
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extrahepatic metastases: one patient with FDG-active
liver metastases had multiple FDG-active lung metasta-
ses. One patient with FDG-active liver metastases had
additional FDG-active bone and lymph node metastases.
One patient with an FDG-active liver metastasis had an
additional histologically proven solitary lung metastasis.
Another patient with an FDG-active liver metastasis
had additional FDG-active peritoneal metastases. The
combination of FDG-inactive liver metastases and FDG-
active extrahepatic deposits occurred in none of the
patients.
Only 2 (14%) of 14 patients with CM had no
extrahepatic metastases. The other 12 (86%) patients with
CM had extrahepatic metastases in the following local-
izations: lymph nodes (10 patients), bone (5), lung (5), soft
tissue (3), spleen (2), adrenal (2) and brain (1).
Outcome
There was an almost significant trend for a better
outcome of the patients with liver metastases from UM
compared to CM (p=0.06). Of 12 patients with UM liver
metastases, 5 (42%) died during follow-up and 11 of 14
(79%) patients with CM liver metastases died during
follow-up. The mean overall survival of patients with UM
liver metastases was 26.8 months (range: 2–59) and
6.5 months (range: 2–27) in the CM group. Two of seven
survivors with UM are in complete remission with normal
PET/CT examinations and S-100B serum markers after 15
and 6 months of follow-up. Two of three survivors with
CM liver metastases are alive in complete remission with
normal PET/CT examinations and S-100B serum markers
after 36 and 37 months follow-up. One patient with UM
was lost to follow-up.
Discussion
Our data show that FDG PET has limited value for the
detection of liver metastases from uveal melanoma. This
evidence is new and our findings contradict the experience
of other authors in patients with uveal melanoma: Francken
and co-authors reported on 17 patients with ocular
melanoma and liver metastases, 9 confirmed by histology.
Fig. 3 A 64-year-old male
patient (patient 27) 5 years after
resection of a CM at the ear
(Breslow 0.71 mm). FDG PET/
CT images (a, b, c, d) show a
solitary liver lesion (arrows)
with high FDG uptake (SUVmax:
10.8). S-100B value was nor-
mal. No extrahepatic metastases
were detectable. The liver lesion
was resected and metastasis of a
CM was confirmed
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Four patients had negative PET scans, supported by
negative anatomical imaging or uneventful follow-up.
Sensitivity for the detection of liver metastases was 100%,
specificity 67% and accuracy 90%. Kurli and co-workers
imaged 20 patients with suspected choroidal melanoma
metastases with FDG PET/CT and found metastases in
8 (40%) patients. The liver was involved in all eight
patients with metastases. No false-negative PET finding
was reported in this study [28]. Other authors used FDG
PET/CT as a screening tool in patients with choroidal
melanoma for initial staging. The same group found
metastases in 2 of 52 (3.8%) patients with choroidal
melanoma at initial staging before treatment [29]. In this
study again no false-negative PET/CT was observed.
Comparing the cited studies with our results and
searching for a reason for the marked difference in
sensitivity of PET regarding UM liver metastases the
following points can be made: there was contemporane-
ously morphological imaging with CT and MRI in the
majority of the cited studies and follow-up of at least
6 months available as sufficient reference standard. The
PET/CT imaging protocol and injected doses were similar
in the cited studies. It seems that in the two studies of Kurli
et al. only patients with PET-positive lesions underwent
Table 2 Box plots of SUVmax values of liver metastases from UM and CM
UM= uveal melanoma, CM=cutaneous melanoma, SUV= standard uptake value. * SUV max. of patient No.13. ° SUV max. of patient No. 9.
Fig. 4 Liver metastasis
(patient 27) of a predominantly
epitheloid, pigmented dermal
malignant melanoma. Residual
liver tissue at lower left
(a). H&E staining, original
magnification ×100. b Immuno-
histochemical positivity (red
reaction product) for the
melanocytic marker S-100,
original magnification ×200.
c Focal immunohistochemical
positivity of the melanoma
cells for GLUT-1 (brown
reaction product). Original
magnification ×200
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biopsy but not patients with suspicious CT scans but
negative PET. With the experience of our study a negative
PET in UM cannot “overrule” a suspicious liver finding on
MRI or CT and this different approach might explain the
different results of the studies. Otherwise we found no
obvious explanation for the apparent differences.
Furthermore, our results indicate that S-100B serum maker
is not sensitive enough for the detection of metastases in UM
patients: we found four patients with normal values of S-100B
tumour markers with proven liver metastases from UM. This
evidence is also new and contradicts previous reports showing
that elevated S-100B markers correlate well with metastatic
UM to the liver [23]. Other authors found no prognostic
value of S-100B serum concentrations in patients with UM
[25]. Also other serum markers like osteopontin (OP) and
melanoma inhibitory activity (MIA) are discussed contro-
versially in the literature for the detection of UM metastases
[23]. Other blood tests like gamma-glutamyl transpeptidase
and alkaline phosphatase showed no sufficient accuracy in
the detection of liver metastases from UM [30]. In our
experience there is no reliable serum marker for the detection
of UM liver metastases.
Our comparison of tumour marker, FDG uptake and
outcome in patients with UM and CM underlines that these
are markedly different melanoma entities with different
biological behaviour. Research is ongoing to better understand
the molecular characteristics of UM liver metastases [31, 32].
It has been shown in vivo and in vitro in different tumour
entities that the expression of GLUT transporters on tumour
cell membranes can correlate with FDG uptake [33–36].
Histopathological evaluation of the resected liver metastases
with GLUT-1 transporters gave no clear explanation for the
decreased FDG uptake in our patients with UM liver
metastases. There was no striking difference in GLUT-1
transporter or tumour cell density between patients with PET-
negative and PET-positive metastases. We had only a limited
number of histological results available and further investiga-
tion of other transporters or hexokinase might correlate better
with the FDG uptake like shown in cholangiocellular carcino-
ma [37]. Whether the trend to more epithelial growth in FDG-
inactive liver metastases from uveal melanoma observed in
two patients of our study has an influence on FDG uptake
must be evaluated further in larger patient numbers.
Like in other tumours the FDG uptake seems to correlate
with the aggressiveness of the tumour biology as patients
with liver metastases of CM had a significantly worse
outcome compared with UM patients with liver metastases
[38]. Obviously, as shown before, the liver is often the first
organ involved in UM while in CM the liver is often
involved together with multiple other organs in a more
advanced stage [7], another reason for the bad outcome.
MR might be the most accurate imaging modality in
FDG-negative liver metastases from uveal melanoma and
we recommend that MRI be performed to evaluate the
whole extent of liver involvement prior to therapy in
particular cases, especially if resection of liver metastases is
considered [39].
Our study has several limitations. This is a retrospective
study. S-100B measurements were not available in all
patients, and histopathological proof is obviously not
available for all metastases. We think that our reference
standard with close clinical follow-up and PET/CT follow-
up in many patients is sufficient.
Our results have direct impact on our PET/CT imaging
protocol. On the basis of these findings we have started to
add a contrast-enhanced CT of the liver in patients with UM
to increase the sensitivity for the detection of liver
metastases of PET/CT in order to also detect FDG-
inactive metastases. In patients with CM we continue to
perform a native low-dose CT as part of the PET/CT
examination.
In conclusion, FDG-PET/CT and S-100B are not
sensitive enough for the detection of liver metastases from
UM, whereas liver metastases from cutaneous melanomas
are reliably FDG positive and lead regularly to increased S-
100B tumour markers. The pathophysiological reasons for
the lower FDG uptake in UM liver metastases remain
unclear. We recommend that a contrast-enhanced PET/CT
protocol be performed in patients with UM in order to
avoid false-negative findings in the liver.
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